AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$INCY

CAGNONI PABLO J sold $1.4M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 10,801 shares of INCYTE CORP (INCY) at $125.56 ($1.36M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Aug 20, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INCY
Bearish
medium confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYBearishLow
01

Why it matters

The disclosed sale provides fresh information on insider sentiment, which can influence short‑term trading decisions.

02

Market read

First‑report insider sale; may affect INCY's stock price in the near term.

03

What to watch

The insider retains 183,200 shares, representing a substantial stake that may temper negative sentiment.

Relevance 5/10Novelty 6/10Timing: post‑market today

Background

SEC Form 4 filing discloses an insider transaction for INCYTE Corp (NASDAQ: INCY).

Company-level read

Ticker impact

$INCYBearishMedium confidence
Context

President Pablo Cagnoni sold 10,801 shares for $1.36M via a 10b5‑1 plan on 2026‑08‑19.

Expected impact

Potential short‑term dip of 2‑4% as market digests the sale.

Evidence & confidence

The sale size is modest relative to float, but the insider's senior role and use of a pre‑arranged plan suggest a material signal.

Market effects

Sector

Minimal impact on the biotech sector; insider activity is company‑specific.

Regional

No broader regional effect.

Global

Limited to investors tracking INCY.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

  • Officer
    Pablo Cagnoni

    President, Global Head of R&D at INCY

  • Company
    INCYTE Corp

    Biotech company listed on NASDAQ under ticker INCY

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INCY insider trading history →

Related articles

OCT 13
Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

tradingview.com1 min
OCT 13
$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

pharmaphorum.com2 min
OCT 7
$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.

simplywall.st2 min